Salvage therapy in Hodgkin's lymphoma

Oncologist

Volumn 14, Issue 4, 2009, Pages 425-432

  Mendler, Jason H ^a   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Hodgkin; Lymphoma; Refractory; Relapse; Salvage; Transplant

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; NAVELBINE; RITUXIMAB;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER TRANSPLANTATION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HODGKIN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; PLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 66249122377     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0002     Document Type: Review

References (59)

1. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395. (Pubitemid 36682817)
2. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 2003;21:607-614. (Pubitemid 46621893)
3. Sureda A, Arranz R, Iriondo A et al. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autologo de Médula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395-1404. (Pubitemid 32202546)
4. Gutierrez-Delgado F, Holmberg L, Hooper H et al. Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003;32:279-285. (Pubitemid 36927079)
5. Martín A, Fernández-Jiménez MC, Caballero MD et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001;113:161-171. (Pubitemid 32423317)
6. Sirohi B, Cunningham D, Powles R et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1312-1319.
7. Moskowitz CH, Kewalramani T, Nimer SD et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-652. (Pubitemid 38297098)
8. Gopal AK, Metcalfe TL, Gooley TA et al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: The Seattle experience. Cancer 2008;113:1344-1350.
9. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
10. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: Current status. The Oncologist 2003;8:438-447. (Pubitemid 37238871)
11. Jabbour E, Hosing C, Ayers G et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007;109:2481-2489. (Pubitemid 46906468)
12. Josting A, Raemakers JM, Diehl V et al. New concepts for relapsed Hodgkin's disease. Ann Oncol 2002;13(suppl 1):117-121. (Pubitemid 34567415)
13. Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999;93:3632-3636. (Pubitemid 29249808)
14. Aparicio J, Segura A, Garcerá S et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10:593-595. (Pubitemid 29305439)
15. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623. (Pubitemid 32113392)
16. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000;18:2615-2619. (Pubitemid 30432529)
17. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-1079. (Pubitemid 47053777)
18. Santoro A, Magagnoli M, Spina M et al. Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92:35-41. (Pubitemid 46232656)
19. Kuruvilla J, Nagy T, Pintilie M et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006;106:353-360. (Pubitemid 43100444)
20. Josting A, Nogová L, Franklin J et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522-1529. (Pubitemid 46260041)
21. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051-1054. (Pubitemid 23114397)
22. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:A randomised trial. Lancet 2002;359:2065-2071. (Pubitemid 34680969)
23. Fermé C, Mounier N, Diviné M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002;20:467-475. (Pubitemid 34072531)
24. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-813. (Pubitemid 27121273)
25. Perea G, Altés A, Montoto S et al. Prognostic indexes in follicular lymphoma: A comparison of different prognostic systems. Ann Oncol 2005;16:1508-1513. (Pubitemid 41222424)
26. Sureda A, Constans M, Iriondo A et al. Prognostic factors affecting longterm outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-633. (Pubitemid 40613330)
27. Constans M, Sureda A, Terol MJ et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome. Ann Oncol 2003;14:745-751. (Pubitemid 36621775)
28. Sweetenham JW, Carella AM, Taghipour G et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999;17:3101-3109. (Pubitemid 29470638)
29. Stiff PJ, Unger JM, Forman SJ et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529-539. (Pubitemid 38351797)
30. Wheeler C, Eickhoff C, Elias A et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997;3:98-106. (Pubitemid 127529983)
31. Brice P, Bouabdallah R, Moreau P et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant 1997;20:21-26. (Pubitemid 27341598)
32. Fung HC, Stiff P, Schriber J et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007;13:594-600. (Pubitemid 46585934)
33. Brice P, Divine M, Simon D et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 1999;10:1485-1488. (Pubitemid 30017059)
34. Josting A, Rudolph C, Mapara M et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116-123.
35. Kewalramani T, Nimer SD, Zelenetz AD et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32:673-679. (Pubitemid 37258622)
36. Radman I, Basic N, Labar B et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002;13:1650-1655.
37. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008;2008:326-333.
38. Laport GG. Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: A concise review. Leuk Lymphoma 2008;49:1854-1859.
39. Anderson JR, Jenkin RD, Wilson JF et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Children's Cancer Group. J Clin Oncol 1993;11:1024-1032. (Pubitemid 23163340)
40. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991;77:649-653.
41. Akpek G, Ambinder RF, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001;19:4314-4321. (Pubitemid 33096779)
42. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572-578. (Pubitemid 26051023)
43. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996;14:1291-1296.
44. Alvarez I, Sureda A, Caballero MD et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006;12:172-183. (Pubitemid 43138012)
45. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934-1941. (Pubitemid 40797503)
46. Sureda A, Robinson S, Canals C et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455-462.
47. Thomson KJ, Peggs KS, Smith P et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008;41:765-770.
48. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheralblood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000;18:3918-3924.
49. Wahl AF, Klussman K, Thompson JD et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-3742. (Pubitemid 34728855)
50. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-2769. (Pubitemid 47123185)
51. Blum KA, Johnson JL, Jung S-H et al. Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma: CALGB 50502. Blood 2008;112:92.
52. Younes A, Forero-Tores A, Bartlett NL et al. Multiple complete responses in a phase 1 dose escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood 2008;112:370.
53. Oki Y, Pro B, Fayad LE et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831-836.
54. Younes A, Romaguera J, Hagemeister F et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-314. (Pubitemid 36828455)
55. Blum KA, Johnson JL, Niedzwiecki D et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-1319. (Pubitemid 47079358)
56. Mendler JH, Kelly J, Voci S et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1759-1764.
57. Trelle S, Sezer O, Naumann R et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: Results of a prematurely closed phase II study (NCT00148018). Haematologica 2007;92:568-569.
58. Younes A, Fanale M, Pro B et al. A phase II study of a novel oral isotope-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2007;25(18 suppl):8000.
59. Fehniger TA, Larson S, Trinkaus K et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary results. Blood 2008;112:899-900.